

**Najważniejsze publikacje za rok 2020
z Kliniki Chorób Zakaznych i Hepatologii**

1: **Flisiak R**, Parczewski M, Horban A, Jaroszewicz J, Koziółewicz D, Pawłowska M, Piekarska A, Simon K, Tomasiewicz K, Zarębska-Michaluk D. Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists. Annex no. 2 as of October 13, 2020. *Pol Arch Intern Med.* 2020 Oct 29;130(10):915-918. doi: 10.20452/pamw.15658. Epub 2020 Oct 29. PMID: 33119223.

IF: 3,007 MNiSW: 100

2: Zarębska-Michaluk D, **Flisiak R**, **Flisiak-Jackiewicz M**. Management of hepatitis B and hepatitis C coinfection: an expert review. *Expert Rev Anti Infect Ther.* 2020 Oct;18(10):1033-1044. doi: 10.1080/14787210.2020.1776112. Epub 2020 Jun 24. PMID: 32579414.

IF: 3,767 MNiSW: 100

3: Jaroszewicz J, Pawłowska M, Simon K, Zarębska-Michaluk D, Lorenc B, Klapaczyński J, Tudrujek-Zdunek M, Sitko M, Mazur W, Janczewska E, Paluch K, Dybowska D, Buczyńska I, Czauż-Andrzejuk A, Berak H, Krygier R, Piasecki M, Dobracka B, Citko J, Piekarska A, Socha Ł, Deroń Z, Tronina O, Laurans Ł, Białkowska J, Tomasiewicz K, Halota W, **Flisiak R**. Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfecting patients treated with DAA. *Expert Rev Anti Infect Ther.* 2020 Oct;18(10):1045-1054. doi: 10.1080/14787210.2020.1782189. Epub 2020 Jun 27. PMID: 32538232.

IF: 3,767 MNiSW: 100

4: **Flisiak R**, Horban A, Jaroszewicz J, Koziółewicz D, Pawłowska M, Parczewski M, Piekarska A, Simon K, Tomasiewicz K, Zarębska-Michaluk D. Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists. Annex no. 1 as of June 8, 2020. *Pol Arch Intern Med.* 2020 Jun 25;130(6):557-558. doi: 10.20452/pamw.15424. Epub 2020 Jun 8. PMID: 32529822.

IF: 3,007 MNiSW: 100

5: **Rogalska-Płońska M**, Kuźmich A, **Łapiński TW**, **Flisiak R**. Abnormalities on chest computed tomography in patients with coronavirus disease 2019. *Pol Arch Intern Med.* 2020 Jun 25;130(6):541-543. doi: 10.20452/pamw.15363. Epub 2020 May 18. PMID: 32420708.

IF: 3,007 MNiSW: 100

6: Marcellin P, Xie Q, Woon Paik S, **Flisiak R**, Piratvisuth T, Petersen J, Asselah T, Cornberg M, Ouzan D, Foster GR, Papatheodoridis G, Messinger D, Regep L, Bakalos G, Alshuth U, Lampertico P, Wedemeyer H. Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B. *PLoS One.* 2020 Apr 10;15(4):e0230893. doi: 10.1371/journal.pone.0230893. PMID: 32275726; PMCID: PMC7147799.

IF: 2,74 MNiSW: 100

7: **Flisiak R**, Horban A, Jaroszewicz J, Kozielowicz D, Pawłowska M, Parczewski M, Piekarska A, Simon K, Tomasiewicz K, Zarębska-Michaluk D. Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of March 31, 2020. *Pol Arch Intern Med.* 2020 Apr 30;130(4):352-357. doi: 10.20452/pamw.15270. Epub 2020 Mar 31. Update in: *Pol Arch Intern Med.* 2020 Jun 25;130(6):557-558. PMID: 32231173.

IF: 3,007 MNiSW: 100

8: **Flisiak R**, Zarębska-Michaluk D, Jaroszewicz J, Lorenc B, Klapaczyński J, Tudrujek-Zdunek M, Sitko M, Mazur W, Janczewska E, Pabjan P, Dybowska D, Buczyńska I, Czauż-Andrzejuk A, Belica-Wdowik T, Berak H, Krygier R, Piasecki M, Dobracka B, Citko J, Piekarska A, Socha Ł, Deroń Z, Tronina O, Laurans Ł, Białkowska J, Tomasiewicz K, Halota W, Simon K, Pawłowska M. Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection. *Pol Arch Intern Med.* 2020 Feb 27;130(2):163-172. doi: 10.20452/pamw.15181. Epub 2020 Feb 7. PMID: 32031541.

IF: 3,007 MNiSW: 100

9: Zarębska-Michaluk D, Piekarska A, Jaroszewicz J, Klapaczyński J, Mazur W, Krygier R, Belica-Wdowik T, Baka-Ćwierz B, Janczewska E, Pabjan P, Dobracka B, Lorenc B, Tudrujek-Zdunek M, Tomasiewicz K, Sitko M, Garlicki A, Czauż-Andrzejuk A, Citko J, Dybowska D, Halota W, Pawłowska M, Laurans Ł, Deroń Z, Buczyńska I, Simon K, Białkowska J, Tronina O, **Flisiak R**. Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis. *Adv Med Sci.* 2020 Mar;65(1):12-17. doi: 10.1016/j.advms.2019.09.002. Epub 2019 Dec 13. PMID: 31841821.

IF: 2,57 MNiSW: 100

10: Lawitz E, **Flisiak R**, Abunimeh M, Sise ME, Park JY, Kaskas M, Bruchfeld A, Wörns MA, Aglitti A, Zamor PJ, Xue Z, Schnell G, Jalundhwala YJ, Porcalla A, Mensa FJ, Persico M. Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. *Liver Int.* 2020 May;40(5):1032-1041. doi: 10.1111/liv.14320. Epub 2019 Dec 26. PMID: 31821716.

IF: 5,175 MNiSW: 100

11: Zarębska-Michaluk D, Jaroszewicz J, Buczyńska I, Simon K, Lorenc B, Tudrujek-Zdunek M, Tomasiewicz K, Sitko M, Garlicki A, Janczewska E, Dybowska D, Halota W, Pawłowska M, Pabjan P, Mazur W, Czauż-Andrzejuk A, Berak H, Horban A, Socha Ł, Klapaczyński J, Piekarska A, Blaszkowska M, Belica-Wdowik T, Dobracka B, Tronina O, Deroń Z, Białkowska-Warzecha J, Laurans Ł, **Flisiak R**. Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4. *J Gastroenterol Hepatol.* 2020 Jul;35(7):1238-1246. doi: 10.1111/jgh.14936. Epub 2020 Jan 16. PMID: 31734959.

IF: 3,437 MNiSW: 100

12: Piekarska A, Jabłonowska E, Garlicki A, Sitko M, Mazur W, Jaroszewicz J, Czauz-Andrzejuk A, Buczyńska I, Simon K, Lorenc B, Dybowska D, Halota W, Pawłowska M, Dobracka B, Berak H, Horban A, Tudrujek-Zdunek M, Tomasiewicz K, Janczewska E, Socha Ł, Laurans Ł, Parczewski M, Zarębska-Michaluk D, Pabjan P, Belica-Wdowik T, Baka-Ćwierz B, Deroń Z, Krygier R, Klapaczyński J, Citko J, Berkan-Kawińska A, **Flisiak R**. Real life results of direct acting antiviral therapy for HCV infection in HIV-HCV-coinfected patients: Epi-Ter2 study. *AIDS Care*. 2020 Jun;32(6):762-769. doi: 10.1080/09540121.2019.1645808. Epub 2019 Jul 25. PMID: 31345052.
IF: 1,894 MNiSW: 100

13. **Parfieniuk-Kowerda A, Grubczak K, Eljaszewicz A, Świdorska M, Maciaszek M, Panasiuk A, Jaroszewicz J, Flisiak R, Moniuszko M**. High CD163 Expression on Classical Monocytes Is Associated with Immune Control of HBV Infection in Noncirrhotic Patients. *Mediators of inflammation* 2020; MAR 29: 6364258; DOI: 10.1155/2020/6364258
IF: 3,758 MNiSW: 100